Childhood Oncology Fundraising Event
The Andrysik Lab from the Department of Biology, Faculty of Medicine, partnered with The Krtek Children's Oncology Endowment Fund to host a successful fundraising event benefiting children with cancer.
The Biology department is once again organizing the Annual PhD Conference in Biomedical Sciences, which will take place on the 5th - 6th of November 2025 at the University Campus in Brno.
More than 60 PhD students from various departments of the Faculty of Medicine, CEITEC MU, and FNUSA-ICRC will present the progress and results of their doctoral research in the field of biomedicine.
The Annual PhD Conference in Biomedical Sciences brings together PhD students from diverse fields, offering them the opportunity to present their research to a broad audience and to foster open discussions among participants.
The conference unites students from all three specializations under the motto “More people, more science & more fun!”. All students take an active role in shaping the event, encouraging the exchange of ideas, and promoting communication across departments.
This year, the entire conference will take place in the CEITEC MU Atrium. The event starts on November 5, with registration open from 08:00 to 08:30.
The conference will run for two days. In total, eleven students will give talks as part of their doctoral state exams, four students will present their progress reports, and thirty-two students will showcase their work during two poster sessions, providing an excellent environment for networking.
Please see the detailed conference program and the book of abstracts for more information.
We believe that the PhD Conference will create an inspiring and collaborative atmosphere for all participants.
The Andrysik Lab from the Department of Biology, Faculty of Medicine, partnered with The Krtek Children's Oncology Endowment Fund to host a successful fundraising event benefiting children with cancer.
An international team of scientists from Lenka Bešše's laboratory at the Department of Biology and colleagues from German and Swiss institutions have published joint research results on the effects of proteasome inhibition in multiple myeloma. These results offer new possibilities for using already approved and clinically available drugs.